Due to the unavailability of the raw material global bovine insulin API, Wockhardt has been forced to discontinue the Hypurin® Bovine Insulin range.

The company says that residual bovine insulin stocks will be carefully managed to ensure product remains available for patients for as long as possible. However, all patients using Hypurin® Bovine Insulin will need to have their prescription changed.

The company emphasises that the discontinuation of Hypurin® BOVINE Insulin does not affect the supply of Hypurin® PORCINE Insulin.

You can find monthly updates on depletion dates on the company website here.

For medical information call +44 1978 669260 or for supply enquiries call +44 1978 669359


Healthwatch - December 2018

Brian Collett brings you the month's research news...

Increase in October concession price for Risperidone

The PSNC has announced that last month’s price concession for a pack of 60 Risperidone 2mg tablets has risen to &p...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Independent Pharmacist's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.